Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2005 5
2006 3
2007 1
2008 6
2009 7
2010 5
2011 4
2012 8
2013 4
2014 9
2015 5
2016 6
2017 7
2018 3
2019 6
2020 2
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

78 results
Results by year
Filters applied: . Clear all
Page 1
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. Mill CP, et al. Among authors: fiskus w. Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25. Blood. 2019. PMID: 31023702 Free PMC article.
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.
Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Jain N, et al. Among authors: fiskus w. Sci Transl Med. 2019 Jun 19;11(497):eaav5599. doi: 10.1126/scitranslmed.aav5599. Sci Transl Med. 2019. PMID: 31217338 Free PMC article.
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Saenz DT, et al. Among authors: fiskus w. Blood. 2020 Apr 9;135(15):1255-1269. doi: 10.1182/blood.2019002922. Blood. 2020. PMID: 32068780 Free PMC article.
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Saenz DT, et al. Among authors: fiskus w. Leukemia. 2019 Jun;33(6):1373-1386. doi: 10.1038/s41375-018-0334-3. Epub 2018 Dec 21. Leukemia. 2019. PMID: 30575820
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Saenz DT, et al. Among authors: fiskus w. Leukemia. 2017 Sep;31(9):1951-1961. doi: 10.1038/leu.2016.393. Epub 2017 Feb 2. Leukemia. 2017. PMID: 28042144 Free PMC article.
Targeting cistrome and dysregulated transcriptome of post-MPN sAML.
Verstovsek S, Fiskus W, Manshouri T, Bhalla KN. Verstovsek S, et al. Among authors: fiskus w. Oncotarget. 2017 Oct 11;8(55):93301-93302. doi: 10.18632/oncotarget.21752. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212143 Free PMC article. No abstract available.
HDAC inhibitors and chaperone function.
Rao R, Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. Rao R, et al. Among authors: fiskus w. Adv Cancer Res. 2012;116:239-62. doi: 10.1016/B978-0-12-394387-3.00007-0. Adv Cancer Res. 2012. PMID: 23088873 Review.
78 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page